Heron Therapeutics, Inc.
HRTX
Positions held
Your positionsHRTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $68.01M | Enterprise value | $174.75M | Trailing P/E | — | Forward P/E | -3.26 |
| PEG | — | Price / book | 11.55 | Beta | 1.63 | Dividend yield | 0.00% |
| Revenue growth | 1.3% | Earnings growth | — | Gross margin | 61.9% | Operating margin | -5.4% |
| Profit margin | -22.5% | ROE | — | ROA | -2.8% | Debt / equity | 21.48 |
| Current ratio | 2.49 | Free cash flow | -$8.84M | Analyst recommendation | none | Mean target | $7.00 |
| 52w high | $1.58 | 52w low | $0.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $37.7M | $34.7M | $40.6M | $38.2M | $37.2M |
| Op margin | -5.4% | -13.7% | 0.1% | -10.7% | -4.4% |
| Net income | -$5.5M | -$8.1M | -$3.0M | -$17.5M | -$2.4M |
| Gross margin | 69.3% | 69.4% | 72.6% | 68.8% | 73.5% |
| Gross profit | $26.1M | $24.1M | $29.5M | $26.3M | $27.3M |
| Operating income | -$2.0M | -$4.8M | $0.0M | -$4.1M | -$1.6M |
- Revenue +9% vs prior quarter ($38M vs $35M).
- Gross margin 69.3% (was 69.4% prior quarter).
- Operating margin expanded to -5.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $155M | $144M | $127M | $108M |
| Op margin | -1.6% | -8.0% | -87.1% | -162.2% |
| Net income | -$20.2M | -$13.6M | -$111M | -$182M |
| Gross margin | 73.3% | 73.2% | 48.8% | 49.0% |
| Gross profit | $114M | $106M | $61.9M | $52.8M |
| Operating income | -$2.5M | -$11.5M | -$111M | -$175M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-11 · --HC Wainwright Downgrades Heron Therapeutics to Neutral From Buy
2026-08-10 · Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ...
2026-08-10 · Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook
2026-08-10 · Heron Therapeutics Q2 Earnings Call Highlights
2026-08-10 · Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-10 · Heron Therapeutics: Q2 Earnings Snapshot
2026-08-05 · BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates
2026-07-27 · Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
2026-07-15 · New Strong Sell Stocks for July 15th
2026-07-12 · Heron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent Decision
Price (daily)
Full chart · RSI · MACD · patterns